Press Releases BioCardia, Inc.

Equities

BCDA

US09060U5074

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.392 ^USD	-1.04%		-2.00%	-40.98%

May. 14	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 01	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	May. 14	PU
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	May. 09	AQ
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	May. 01	AQ
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	Apr. 25	AQ
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	Mar. 27	PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	Mar. 20	AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	Mar. 13	AQ
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	Mar. 12	AQ
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	Mar. 04	AQ
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	Feb. 08	AQ
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	Jan. 31	AQ
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	Jan. 03	AQ
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	Dec. 19	AQ
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes	Dec. 18	AQ
BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K	Dec. 18	PU
BioCardia : Material Event - Form 8-K	Dec. 06	PU
BioCardia : Shareholder Meeting - Form 8-K	Dec. 05	PU
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval	Nov. 29	AQ
BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K	Nov. 16	PU
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules	Nov. 16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioCardia, Inc.

Equities

BCDA

US09060U5074

Press Releases

Filters